The United States Food and Drug Administration (FDA) announced a warning on Tuesday about the weight management drugs Belviq and Belviq XR (lorcaserin).
The trial has not confirmed that lorcaserin was a major contributing factor to the development of cancer, but the FDA wishes to make the public aware of a potential risk. The results of the clinical trial are still under review; a more conclusive announcement will follow once the FDA has completed their evaluation.
Lorcaserin is a prescription medicine approved by FDA in 2012 for use with a reduced-calorie diet and increased physical activity to help encourage weight loss in adults who are obese or are overweight and have weight-related medical problems. Lorcaserin works by increasing feelings of fullness so that less food is eaten. It is available as a tablet (Belviq) and an extended-release tablet (Belviq XR).
Health care professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program through the FDA website. A form for reporting adverse side effects may also be downloaded here or ordered by calling 1-800-332-1088. Paper forms may be sent through the mail via the address on the form or submitted by fax to 1-800-FDA-0178.